NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
AlsFebruaryTrumpIranNuclearMajorDane'sResearchElectionCandidateCampaignPartyNewsDigestSundayTimelinePressureOneMilitaryPrivateStrikesGlobalTariffsNation
AlsFebruaryTrumpIranNuclearMajorDane'sResearchElectionCandidateCampaignPartyNewsDigestSundayTimelinePressureOneMilitaryPrivateStrikesGlobalTariffsNation
All Articles
STAT+: NIH Director Bhattacharya to lead CDC after O’Neill’s exit
STAT News
Published 4 days ago

STAT+: NIH Director Bhattacharya to lead CDC after O’Neill’s exit

STAT News · Feb 18, 2026 · Collected from RSS

Summary

He's the third leader of the public health agency since this summer.

Full Article

WASHINGTON — National Institutes of Health Director Jay Bhattacharya will take on leadership of the Centers for Disease Control and Prevention on an acting basis, an administration official not authorized to speak publicly confirmed to STAT. Bhattacharya is taking the role after the previous acting director, Health and Human Services Department Deputy Secretary Jim O’Neill, exited the department. Bhattacharya will still run NIH, as well. O’Neill will be nominated to run the National Science Foundation, the administration official said. The New York Times first reported the news. Bhattacharya will be the third leader the public health agency has had since summer. Susan Monarez, who was confirmed by the Senate, led the CDC for 28 days before she was fired by health secretary Robert F. Kennedy Jr. after she refused to preemptively sign off on vaccine policy. After her ouster, O’Neill became acting director. O’Neill signed off on changes to reduce the number of recommended pediatric vaccines. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe


Share this story

Read Original at STAT News

Related Articles

STAT News1 day ago
STAT+: Nature Medicine to investigate study that found cancer treatment is better in morning

Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning.

STAT News1 day ago
STAT+: DOJ, Ohio attorney general accuse OhioHealth of driving up prices, crowding out competition

Regulators say Ohio hospital system made it difficult for health insurers to offer cheaper plans.

STAT News1 day ago
STAT+: Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

STAT News2 days ago
STAT+: Element Biosciences launches table-top sequencer capable of $100 genome

And other biotech news brought to you by The Readout newsletter

STAT News2 days ago
STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more

The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV

STAT News2 days ago
ACIP meeting postponed, for reasons that are unclear

And other health news from today's Morning Rounds newsletter